Takeda’s Narcolepsy Drug Candidate Clears Phase 3 | Sleep Review
Takeda’s investigational orexin-2 receptor agonist oveporexton met all endpoints in two phase 3 trials for narcolepsy type 1.| Sleep Review
New research reveals how orexin deficiency may paradoxically improve glymphatic function when NT1 patients are awake.| Sleep Review
Takeda’s investigational orexin-2 receptor agonist oveporexton met all endpoints in two phase 3 trials for narcolepsy type 1.| Sleep Review
